Current HOWL holders face massive dilution (~93% pro-forma ownership loss) as the merger effectively transfers control to Ambros and PIPE investors. The stock may trade down on this structure. Monitor for stockholder vote and S-4 filing for further details. The combined company's value will hinge on neridronate's Phase 3 CRPS-RISE data in 2028, a binary event years away.
Price Chart
Executive Summary
Werewolf Therapeutics (HOWL) announced a definitive all-stock merger with Ambros Therapeutics, valuing Ambros at $500M and Werewolf at $47.5M, with a concurrent $150M oversubscribed private placement. Post-merger, pre-merger Werewolf stockholders will own only ~6.8% of the combined company, which will focus on Ambros' neridronate for CRPS-1, a Phase 3 asset with FDA Breakthrough Therapy designation. The deal effectively transforms HOWL into a new entity (ticker AMBX) with a different pipeline, making this a reverse-merger-like event with massive dilution for current HOWL holders.
Key Financial Metrics
Key Facts
- Werewolf Therapeutics and Ambros Therapeutics entered a definitive all-stock merger agreement.
- Ambros Therapeutics is valued at $500M; Werewolf Therapeutics at $47.5M.
- Concurrent oversubscribed private placement of $150M from healthcare-dedicated investors.
- Pre-merger Werewolf stockholders (excluding PIPE investors) will own ~6.8% of the combined company.
- Pre-merger Ambros stockholders will own ~71.7%; PIPE investors ~21.5%.
- Combined company will focus on neridronate for CRPS-1, a Phase 3 asset with FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.
- Neridronate has been administered to ~600,000 patients in Italy across approved indications.
- CRPS-RISE Phase 3 topline data expected in 2028; cash runway into 1H 2029.
- Transaction expected to close by Q1 2027, subject to stockholder approvals and other conditions.
- Combined company expected to trade under ticker 'AMBX' on Nasdaq.
Financial Impact
Pre-merger Werewolf stockholders diluted to ~6.8% ownership of combined company, implying a ~93% effective dilution from the merger structure. Ambros valued at $500M vs Werewolf at $47.5M. $150M PIPE adds further dilution.
Risk Factors
- Massive dilution for current HOWL stockholders (~93% ownership loss).
- Transaction may not close if stockholders of either company fail to approve.
- Neridronate Phase 3 trial may fail or not support FDA approval despite Breakthrough designation.
- Cash runway only into 1H 2029; additional capital likely needed if approval is delayed.
- Combined company has no approved products and is pre-revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3349041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-4/A | — | awaiting T+5 | — | — |
Sep 22, 2026 4w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $0.9800 (+0.95%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $0.9800 (+0.00%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9800 (+12.13%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9800 (+12.13%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $0.9800 (−12.13%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9800 (+177.54%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9800 (+177.54%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9800 (−172.30%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9800 (−172.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers